Acute Toxicity and Phytochemical analysis of CP Men Capsules in Spraque-Dawleys Rats

Raphael Nyarkotey Obu, RND, PhD¹, Lawrencia Aggrey -Bluwey, BSc, PGDE, MPhil²

¹Nyarkotey College of Holistic Medicine, Tema Community 7, Ghana
²Assistant Lecturer, Department of Health Administration and Education, University of Education, Winneba, Ghana

DOI: 10.36348/sijtcm.2021.v04i06.004 | Received: 12.10.2020 | Accepted: 25.10.2020 | Published: 11.06.2021

*Corresponding author: Raphael Nyarkotey Obu

Abstract

This study was design to examine the acute toxicity of the 80% -ethanolic extract of CP Men capsules in healthy male and female Sprague-Dawley rats and phytochemical screening of the product. Six samples of the product were submitted to the Department of Pharmacology & Toxicology, School of Pharmacy, College of Health Sciences, University of Ghana, Legon, Accra for the analysis and others. The investigators at the University declared in their research report that the study was conducted at the Animal Experimentation Unit of the School of Biomedical and Allied Health Sciences (SBAHS). College of Health Sciences, University of Ghana. On clinical Observation, the study conducted reports that the animals treated by the ethanolic extract of CP Men capsules (5000 mg/kg) did not show any observable abnormality in movement, salivation, sleep, lethargy, there was no signs of piloerection and mortality in comparison to the control group within the first 48 hours, and daily during the 14 days of the study. With regards to Lethal Dose Fifty (LD₅₀), the study found that per monitoring the animals for 24, 48 hours and throughout the remaining 12 days, the group of rats treated by the ethanolic extract of CP Men capsules did not record any deaths. Hence, the LD₅₀ of the ethanolic extract of CP Men capsules, when administered orally, is greater than 5000mg/kg. In conclusion, further studies involving long term administration of aqueous extract of CP Men capsules in different experimental rodents, including mice, will be needed to assess its safety for trial and use in humans. More renal function markers such as creatinine should be analyzed. The phytochemical screening also demonstrates that the herbal drug is of plant origin.

Keywords: CP Men Capsule, Toxicity, clinical observation, Lethal Dose Fifty (LD₅₀), monitoring.

Copyright © 2021 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

‘CP men capsules’ is an herbal supplement produced by Live Long Herbal Centre and is believed to be effective in the treatment of prostate conditions. The product is composed of xylopia aethiopica, zingiber officinalis and annona muricata. The World Health Organization advocates the use of herbal medicines that are proven scientifically to be of good quality, safe and efficacious as affordable alternatives to orthodox medicines for the majority of the world’s populace particularly in low-income countries [1] this is an essential requirement for the registration of newly developed medicinal products [2-4]. The study was done as requested by the Food and Drugs Authority (FDA) of Ghana as part of the registration requirements of the herbal product.

OBJECTIVES

The specific objectives were:

1. To determine the LD₅₀ (Lethal dose) of an 80% -ethanolic extract of CP men capsules in Sprague Dawley rats.
2. To determine the effects on physical signs of toxicity following administration of a very high dose (5000mg/kg) of an 80% -ethanolic extract of CP men capsules.
3. To determine the effect of oral administration of single high-limit dose of CP men capsules on haematological and biochemical parameters of Sprague-Dawley rats.

METHODOLOGY

Experimental design

The study was an acute toxicity and phytochemical study.
Preparation of ethanolic Extract
Two kilograms of the powder were exhaustively extracted using a cold maceration with 80% v/v ethanol for 72 hours in a flat bottom flask. The extract was concentrated with a rotary evaporator at 60°C which produced a semi-solid mass of extract. The semi-solid mass was dried using a water bath at a temperature of 78-79°C and then kept in a desiccator.

Experimental animals and housing
Fourteen Sprague-Dawley rats (Hsd:SD strain), weighing 120-200 (6-9 weeks old) were obtained from the Center for Plant Medicine Research (CPMR), Mampong-Akwapim and kept at the Animal Experimentation Unit of the School of Biomedical and Allied Health Sciences (SBAHS), College of Health Science, University of Ghana, where all experimental procedures were carried out. The Department of Pharmacology & Toxicology (School of Pharmacy, University of Ghana) approved all animal procedures and techniques used in these studies. The animals were housed in groups of six in stainless steel cages (34cm*47cm*18cm) with softwood shavings as bedding. They were fed with normal commercial pellet diet (AGRAMAT, Kumasi) were given access to ad libitum and maintained under laboratory conditions (temperature 25±1°C, Relative humidity 60-70% and 12 hour light-dark cycle). All experiments were conducted during the day cycle between the hours of 7:00-15:00 GMT.

Animal Groupings and Acute Extract administration
The animals were acclimatized for a week and randomly divided into two groups of seven rats each (n=7). The rats fasted overnight before administration. One group received the 80%-ethanolic extract of CP men capsules at 5000mg/kg and the other group received a dose-equivalent volume of saline solution by oral gavage. The administration was done for a day.

48-hour clinical observations and LD₅₀ Determination
The animals were observed for clinical signs of toxidromes such as changes in movement, salivation, sleep, lethargy, piloerection and mortality within 48 hours. Observations were done 30 minutes after administration, and every 6 hours. Mortality after 24 and 48 hour post treatment were recorded and the LD₅₀ (the lethal dose) was determined.

14-day Clinical Observation
The animals were monitored and observed daily for 12 days looking out for any clinically observed toxidromes and mortality. On the 14th day of the study period, the rats were euthanized by cervical dislocation, and blood samples were collected from each animal via cardiac puncture into an ethylene-di-amine-tetra-acetic acid (EDTA) for haematological examination, and gel tubes for biochemical analysis. An automated haematology analysis (URIT-5250Vet, URIT Medical Electronics Co., Ltd., China) was used for the haematological analysis. Haematological indices determined include red blood cell count (RBC), white blood cell count (WBC), haemoglobin concentration (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular haemoglobin concentration (MCHC), planet (PLT), lymphocyte count (LYM), red cell distribution width (RDW), platelet distribution width(PDW), mean platelet volume (MPV) and granulocyte (GRA). The gel tubes were centrifuged immediately after collection at 5000 rpm for 15mins using a benchtop centrifuge (High-Speed Refrigerated Centrifuge TGL-16C, China) sera were pipetted and placed in cryotubes. Serum biochemical analysis was done with a biochemical analyser (Mindray Chemistry Analyzer, BS-200, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., China). The sera were examined for renal function (urea), and liver function (AST-aspartate aminotransferase; ALT- Alanine aminotransferase and ALD alkaline phosphatase).

STATISTICAL ANALYSIS
All data were analyzed using GraphPad Prism version 8.0 Data were expressed as mean± standard error of the mean (mean± SEM). One-way ANOVA was used to test for differences among groups, followed by Newman-Keuls multiple comparison test. P<0.05 was deemed statistically significant.

RESULTS
Clinical observations
The animals treated by the ethanolic extract of CP men capsules (5000 mg/kg) did not show any observable abnormality in movement, salivation, sleep, lethargy, there was no signs of piloerection and mortality in comparison to the control group within the first 48 hours, and daily during the 14 days of the study.

Lethal Dose Fifty (LD₅₀)
On monitoring the animals for 24, 48 hours and throughout the remaining 12 days, the group of rats treated by the ethanolic extract of CP men capsules did not record any deaths. Hence, the LD₅₀ of the ethanolic extract of CP men capsules, when administered orally, is greater than 5000mg/kg.

Haematological analysis
Haematological parameters after a single administration of the ethanolic extract of CP men capsules at 5000 mg/kg in SD rats are presented in table 1. It was observed that, except for mean corpuscular haemoglobin concentration (MCHC), there was no significant difference between the haematological parameters measured in the control group and the group treated by the ethanolic extract of CP men capsules. MCHC is a measure of the average concentration of haemoglobin within a single red blood cell. The MCHC value in the ethanolic extract group was 33.43g/dL and significantly higher (p<0.0001) than the MCHC value...
in the control group. An elevated value of MCHC may either be due to more haemoglobin being concentrated in the red blood cell or to hemolysis of the RBCs. As a result of autoimmune hemolytic anaemia, hereditary spherocytosis or due to severe burns [5]

Serum biochemistry analysis

The serum biochemical markers after a single administration of the ethanolic extract of CP men capsules at 5000 mg/kg in SD rats are presented in table 2. They were grouped as renal function (urea) and liver function markers (alanine aminotransferase – ALT, aspartate aminotransferase- AST and alkaline phosphatase – ALP enzyme assays). Regarding the renal function (urea level), there was no significant difference between the control group and the group treated by ethanolic extract of CP men capsules. With regards to the liver function assessment, there was no significant difference between the control and the ethanolic extract of CP groups. The AST value for the CP treated group that was higher than the control group (160.9±60.00 vs. 82.80±27.55 respectively); however, this decrease was not statistically significant (p=0.4641). The ALP values on the other hand, were slightly lower in the CP-treated group than in the control group (80.70±23.30 vs. 116.2±31.39, respectively) but was not significant (p=0.6316). High AST and ALP values indicate that the liver or any other organ such as the kidney that produces AST and ALP enzymes may be damaged. However, the levels observed were within the normal range and the levels observed are unlikely to be of any clinical relevance. These observations would need further investigations.

Table 1: Haematological parameters after a single administration at 5000mg/kg of an ethanolic extract of CP men capsules in SD rats

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Saline</th>
<th>CP</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC (10^3/mm³)</td>
<td>2.6±0.62</td>
<td>4.8±1.0</td>
<td>0.3288</td>
</tr>
<tr>
<td>RBC (10^6/mm³)</td>
<td>6.8±0.06</td>
<td>6.85±0.30</td>
<td>0.9984</td>
</tr>
<tr>
<td>HGB (g/dl)</td>
<td>12.97±1.13</td>
<td>13.48±0.38</td>
<td>0.4296</td>
</tr>
<tr>
<td>HCT (%)</td>
<td>41.48±0.68</td>
<td>40.38±1.35</td>
<td>0.7085</td>
</tr>
<tr>
<td>MCV (um³)</td>
<td>59.0±0.35</td>
<td>59.17±0.59</td>
<td>0.9685</td>
</tr>
<tr>
<td>MCHC (g/dl)</td>
<td>31.18±0.23</td>
<td>33.43±0.26</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>PLT (10³/mm³)</td>
<td>1076±22.17</td>
<td>1004±53.88</td>
<td>0.3857</td>
</tr>
<tr>
<td>LYM (10^3/mm³)</td>
<td>1.95±0.41</td>
<td>2.65±0.66</td>
<td>0.6610</td>
</tr>
<tr>
<td>MPV (um³)</td>
<td>7.53±0.07</td>
<td>7.33±0.28</td>
<td>0.7477</td>
</tr>
<tr>
<td>GRA (10²/mm³)</td>
<td>0.88±0.11</td>
<td>0.93±0.22</td>
<td>0.8458</td>
</tr>
</tbody>
</table>

Values are expressed as mean +SEM(n=7). P-Value represents significance level for one-way ANOVA (followed by Newman-Keuls Multiple Comparison Test) with * indicating significant difference from the control (distilled water) *=p<0.05, **=p<0.01 and ****=p<0.0001

Table 2: Biochemical analysis after a single administration at 5000mg/kg of an ethanolic extract of CP men capsules in SD rats

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Saline</th>
<th>CP</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea (mmol/L)</td>
<td>1.88±0.68</td>
<td>3.04±0.51</td>
<td>0.3900</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>82.80±27.55</td>
<td>160.9±60.00</td>
<td>0.4641</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>212.7±48.76</td>
<td>326.3±29.11</td>
<td>0.1143</td>
</tr>
<tr>
<td>ALP (U/L)</td>
<td>116.2±31.39</td>
<td>80.70±23.30</td>
<td>0.6316</td>
</tr>
</tbody>
</table>

Values are expressed as mean +SEM(n=7). P-Value represents significance level for one-way ANOVA (followed by Newman-Keuls Multiple Comparison Test) with * indicating significant difference from the control (distilled water) *=p<0.05, **=p<0.01 and ****=p<0.0001

B. ORGANOLEPTIC PROPERTIES

Form  Powder
Colour  Brown
Odour  Spicy

PHYSICOCHEMICAL PROPERTIES

pH  N/A
wt/ml  N/A

PHYTOCHEMICAL PROPERTIES

Reducing sugars  Positive
Saponins  Positive
Tannins  Positive
Alkaloid  Positive
Flavonoid  Positive
Sterols  Positive

CHROMATOGRAPHIC PROFILE

Stationary phase  Silica gel
Mobile phase  Chloroform: Petroleum ether
Sample used  chloroformic extract
Detecting reagent  Anisaldehyde spray reagent
Results Six spots were identified after spraying with detective Reagent (Rf values: 0.47, 0.37, 0.29, 0.22, 0.14, 0.08)

RESULT
From the phytochemical analysis, it can be concluded that the product, CP Men Capsule, with the active ingredients ‘xylopia aethiopica, zingiber officinale, annona muricata’ may be of plant origin.

DISCUSSION
The product CP Men capsule is formulated for prostatic issues with three ingredients; xylopia aethiopica, Zingiber officinale, and Annona muricata.

Xylopia aethiopica
A 2017 study by Adaramoye et al. [10] demonstrates that Xylopia aethiopica induces anti proliferative activity in Prostate cancer cells through a mechanism that involves apoptosis. Therefore, it may be a potential therapeutic agent for Prostate cancer.

Zingiber officinale
A 2014 study by Saha et al. [6] suggest that 6-SHO derived from ginger root may have potential as a chemopreventive and/or therapeutic agent for prostate cancer and that further study of this compound is warranted.

A more recent 2020 study by Obisike et al. [7] demonstrates that ginger rhizome could reduce and inhibit testosterone-induced hyperplasia of the prostate in albino wistar rats and is suggested for further studies, especially in humans. This study used strength of 500 and 1500 mg/kg of ginger rhizome administered orally of 15 days. Additionally, a 2011 study by Karn et al. [11] also used ginger strength of 567mg for a 70kg adult and can be found in a 100g of fresh ginger

Annona muricata
Annona muricata and other plants have been shown to have promising compounds that can be utilized in the treatment of cancer. Native to the tropical and subtropical parts of the world, A. muricata plant extracts contain compounds that are particularly effective against cancer cells according to Yajid et al. [8]. Also Rady et al. [9] review is of the opinion that, A. muricata has anticancer effect.

SUMMARY OF FINDINGS
1. Oral administration of an ethanolic extract of CP men capsules at 5000mg/kg did not cause any sign of toxicity and mortality.
2. The LD₅₀ of orally administered ethanolic extract of CP men capsules is above 5000mg/kg in SD rats
3. Oral administration of ethanolic extract of CP men capsules did not cause any significant changes in the haematological parameters in the SD rats following a day’s exposure.
4. Oral administration of ethanolic extract of CP men capsules did not show any significant changes in the serum biochemistries measured in the SD rats following a day’s exposure.

CONCLUSION
The LD₅₀(Lethal dose) of 80%-ethanol extract of CP men capsules in Sprague-Dawley rats is greater than 5000mg/kg. Further studies involving long term administration of aqueous extract of CP men capsules in different experimental rodents, including mice, will be needed to assess its safety for trial and use in humans. More renal function markers such as creatinine should be analyzed.

ACKNOWLEDGEMENT
To investigators at the Kwame Nkrumah University of Science and Technology(KNUST), Kumasi.

REFERENCES